Lipoxins Regulate the Early Growth Response–1 Network and Reverse Diabetic Kidney Disease

Total Page:16

File Type:pdf, Size:1020Kb

Lipoxins Regulate the Early Growth Response–1 Network and Reverse Diabetic Kidney Disease BASIC RESEARCH www.jasn.org Lipoxins Regulate the Early Growth Response–1 Network and Reverse Diabetic Kidney Disease Eoin P. Brennan,1,2 Muthukumar Mohan,1,3 Aaron McClelland,1 Christos Tikellis,1,3 Mark Ziemann,1,4 Antony Kaspi,1,4 Stephen P. Gray,1 Raelene Pickering,1,3 Sih Min Tan,1,3 Syed Tasadaque Ali-Shah,5 Patrick J. Guiry,5 Assam El-Osta,1,4 Karin Jandeleit-Dahm,1,3 Mark E. Cooper,1,3 Catherine Godson,2 and Phillip Kantharidis1,3 1Juvenile Diabetes Research Foundation Danielle Alberti Memorial Centre for Diabetes Complications, Diabetes Division, Baker IDI Heart and Diabetes Institute, Melbourne, Victoria, Australia; 2University College Dublin Diabetes Complications Research Centre, UCD Conway Institute of Biomolecular and Biomedical Research, UCD School of Medicine and Medical Sciences, and 5Centre for Synthesis and Chemical Biology, UCD School of Chemistry and Chemical Biology, University College Dublin, Dublin, Ireland; and 3Department of Diabetes and 4Epigenetics in Human Health and Disease Laboratory, Department of Diabetes, Central Clinical School, Monash University, Clayton, Victoria, Australia ABSTRACT Background The failure of spontaneous resolution underlies chronic inflammatory conditions, including microvascular complications of diabetes such as diabetic kidney disease. The identification of endoge- nously generated molecules that promote the physiologic resolution of inflammation suggests that these bioactions may have therapeutic potential in the context of chronic inflammation. Lipoxins (LXs) are lipid mediators that promote the resolution of inflammation. Methods We investigated the potential of LXA4 and a synthetic LX analog (Benzo-LXA4)astherapeutics 2 2 in a murine model of diabetic kidney disease, ApoE / mice treated with streptozotocin. Results Intraperitoneal injection of LXs attenuated the development of diabetes-induced albuminuria, mesangial expansion, and collagen deposition. Notably, LXs administered 10 weeks after disease onset also attenuated estab- lished kidney disease, with evidence of preserved kidney function. Kidney transcriptome profiling defined a diabetic signature (725 genes; false discovery rate P#0.05). Comparison of this murine gene signature with that of human diabetic kidney disease identified shared renal proinflammatory/profibrotic signals (TNF-a,IL-1b,NF-kB). In diabetic mice, we identified 20 and 51 transcripts regulated by LXA4 and Benzo-LXA4, respectively, and pathway analysis identified established (TGF-b1, PDGF, TNF-a,NF-kB) and novel (early growth response–1 [EGR-1]) networks acti- vatedindiabetes andregulatedby LXs.Inculturedhuman renal epithelial cells, treatment with LXs attenuated TNF-a–driven Egr-1 activation, and Egr-1 depletion prevented cellular responses to TGF-b1 and TNF-a. Conclusions These data demonstrate that LXs can reverse established diabetic complications and support a therapeutic paradigm to promote the resolution of inflammation. J Am Soc Nephrol 29: 1437–1448, 2018. doi: https://doi.org/10.1681/ASN.2017101112 Received October 19, 2017. Accepted January 23, 2018. Diabetes is recognized as a major epidemic, which has increased in incidence by 50% over E.P.B. and M.M. share first authorship. M.E.C., C.G. and P.K. share the past 15 years.1,2 Diabetic microvascular com- senior authorship. plications include kidney disease (nephropathy) Correspondence: Dr. Phillip Kantharidis, Department of Diabetes, as well as neuropathy and retinopathy.3 Diabetic Central Clinical School, Monash University, Clayton, VIC, Australia or Dr. Eoin Brennan, UCD Diabetes Complications Research Centre, kidney disease (DKD) is the leading cause of UCD Conway Institute of Biomolecular and Biomedical Research, UCD ESRD, affecting approximately 30% of patients School of Medicine and Medical Sciences, University College Dublin, with long-standing type 1 and type 2 diabetes, Ireland. Email: [email protected] or [email protected] and is characterized by proteinuria and gradual Copyright © 2018 by the American Society of Nephrology J Am Soc Nephrol 29: 1437–1448, 2018 ISSN : 1046-6673/2905-1437 1437 BASIC RESEARCH www.jasn.org loss of kidney function.4,5 There is now a growing appreci- Significance Statement ation for the role of chronic low-grade inflammation as a common pathogenic mechanism. Evidence from clinical Impaired resolution of inflammation underlies chronic conditions, studies suggests that inflammatory markers including including microvascular complications of diabetes such as diabetic TNF-a, IL-1, IL-6, and monocyte chemoattractant protein kidney disease (DKD). Lipoxins (LXs) are lipid mediators that pro- mote the resolution of inflammation. Here, we investigated the 1 (MCP-1) are elevated in patients with diabetes (type 1 and potential of LXA4 and a synthetic LX analogue (Benzo-LXA4) as type 2), and that their levels may predict the onset and pro- therapeutics in a murine model of DKD (streptozotocin diabetic 2 2 gression of diabetic complications.6–11 ApoE / mouse). The development of diabetes-induced albumin- The failed resolution of inflammation may be a major uria, mesangial expansion, and collagen deposition was attenuated fi fi contributor to the pathogenesis of diabetes, CVD, and as- by LXs. Kidney transcriptome pro ling de ned a diabetic signature, and LX-mediated transcriptome responses. Using human renal 12–15 fi sociated complications. The identi cation of endoge- epithelial cells, we demonstrate that LXs attenuate Egr-1 activation. nous mediators that promote resolution, including lipids These data demonstrate for the first time that LXs can reverse es- and cytokines, provides a template for potential mimicry tablished diabetic complications and support a therapeutic para- and avoiding the complications associated with chronic digm to promote the resolution of inflammation. 12,16–25 anti-inflammatory approaches. Lipoxin A4 (LXA4) fl is an eicosanoid generated during acute in ammatory re- In Vitro Studies fl sponses that promotes the resolution of in ammation via Immortalized human kidney epithelial cells (HK-2; ECACC, the G-protein coupled receptor formyl peptide receptor 2 Porton Down, UK) were cultured at 37°C in a humidified 19,26,27 (ALX/FPR2). Here, we have explored the potential of atmosphere of 95% air/5% CO2, and maintained in DMEM- LXA4 and a synthetic analog, Benzo-LXA4,tomodulate F12 (Sigma-Aldrich, Steinheim, Germany) supplemented with DKD in a murine model (streptozotocin [STZ]-treated 2 mM L-glutamine, 100 U/ml penicillin, 100 mg/ml streptomy- 2/2 ApoE mice). This model combines the genetic deletion cin, 10 ng/ml epidermal growth factor, 36 ng/ml hydrocortisone, of apo E, leading to hyperlipidemia, with STZ-mediated and 3 pg/ml triiodothyronine; and 5 mg/ml insulin, 5 mg/ml b pancreatic islet cell ablation, leading to diabetes, ulti- transferrin, and 5 ng/ml selenium solution (Sigma-Aldrich). Af- mately driving a more severe and accelerated renal in- ter serum restriction for 24 hours, cells were stimulated with ve- jury.28–36 We report that LXs attenuate the development hicle (0.1% ethanol), LXA4 (0.1 nM), or Benzo-LXA4 (1 nM) for of proteinuria and glomerular injury in diabetic mice. 30 minutes and media was removed and replaced with media with Most noteworthy are our data that show that LXs reverse or without TGF-b1(10ng/ml;PromoCellGmbH). established renal damage. We have investigated the under- lying mechanisms for these responses via high-throughput fi sequencing of renal tissue and have identified specific Renal RNA-Seq Pro ling networks of gene expression induced by diabetes and sus- Detailed methods are available on RNA-seq and bioinfor- fl ceptible to regulation by LXs including Egr-1. matic analysis in the Supplemental Material. Brie y, RNA was isolated from kidney Trizol homogenates using the Direct-zol RNA MiniPrep Kit (Zymo Research; n=6 kid- METHODS neys per treatment group). Normalized read counts for all genes in all samples are detailed in Supplemental Table 9. Tran- , In Vivo Preclinical Studies scripts with a false discovery rate (FDR) P value 0.05 were 2 2 fi Six-week-old ApoE / male mice (C57BL/6 background) deemed statistically signi cant. Upstream regulator analysis of were rendered diabetic by five daily intraperitoneal (ip) differentially expressed gene sets was performed using the Inge- injections of STZ (Sigma-Aldrich, St Louis, MO) at a nuity Pathway Analysis Z-score algorithm (Qiagen). Analysis of 2 2 dose of 55 mg/kg. ApoE / mice were administered either promoters for enriched TFBSs was performed using Genomatix Matbase (Genomatix). RNA-seq data are deposited at the Gene ethanol (0.1%), LXA4 (5 mg/kg;Merck,Calbiochem),or Expression Omnibus (GSE107942). Benzo-LXA4 (1.7 mg/kg; synthesized at University College Dublin, Ireland37) twice weekly by ip injection. For the prevention study design, mice were followed for 10 or Statistical Analyses 20 weeks, and were administered ethanol, LXA4,or All statistical analyses were performed utilizing GraphPad Benzo-LXA4 between weeks 1 and 10 or weeks 1 and 20, Prism software. Experiments with only one treatment were respectively. For the intervention study design, mice were assessed by t test. Experiments with multiple treatment followed for 16 weeks, and were administered ethanol, groups were analyzed by one-way ANOVAwith post hoc com- LXA4, or Benzo-LXA4 between weeks 10 and 16. Blood glu- parisons of group means performed by Fisher’s least signifi- cose levels were monitored weekly after STZ injections cant difference method. A P value #0.05 was considered for the duration of the studies
Recommended publications
  • SRC Antibody - N-Terminal Region (ARP32476 P050) Data Sheet
    SRC antibody - N-terminal region (ARP32476_P050) Data Sheet Product Number ARP32476_P050 Product Name SRC antibody - N-terminal region (ARP32476_P050) Size 50ug Gene Symbol SRC Alias Symbols ASV; SRC1; c-SRC; p60-Src Nucleotide Accession# NM_005417 Protein Size (# AA) 536 amino acids Molecular Weight 60kDa Product Format Lyophilized powder NCBI Gene Id 6714 Host Rabbit Clonality Polyclonal Official Gene Full Name V-src sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog (avian) Gene Family SH2D This is a rabbit polyclonal antibody against SRC. It was validated on Western Blot by Aviva Systems Biology. At Aviva Systems Biology we manufacture rabbit polyclonal antibodies on a large scale (200-1000 Description products/month) of high throughput manner. Our antibodies are peptide based and protein family oriented. We usually provide antibodies covering each member of a whole protein family of your interest. We also use our best efforts to provide you antibodies recognize various epitopes of a target protein. For availability of antibody needed for your experiment, please inquire (). Peptide Sequence Synthetic peptide located within the following region: QTPSKPASADGHRGPSAAFAPAAAEPKLFGGFNSSDTVTSPQRAGPLAGG This gene is highly similar to the v-src gene of Rous sarcoma virus. This proto-oncogene may play a role in the Description of Target regulation of embryonic development and cell growth. SRC protein is a tyrosine-protein kinase whose activity can be inhibited by phosphorylation by c-SRC kinase. Mutations in this gene could be involved in the
    [Show full text]
  • Download (PDF)
    ANALYTICAL SCIENCES NOVEMBER 2020, VOL. 36 1 2020 © The Japan Society for Analytical Chemistry Supporting Information Fig. S1 Detailed MS/MS data of myoglobin. 17 2 ANALYTICAL SCIENCES NOVEMBER 2020, VOL. 36 Table S1 : The protein names (antigens) identified by pH 2.0 solution in the eluted-fraction. These proteins were identified one or more out of six analyses. Accession Description P08908 5-hydroxytryptamine receptor 1A OS=Homo sapiens GN=HTR1A PE=1 SV=3 - [5HT1A_HUMAN] Q9NRR6 72 kDa inositol polyphosphate 5-phosphatase OS=Homo sapiens GN=INPP5E PE=1 SV=2 - [INP5E_HUMAN] P82987 ADAMTS-like protein 3 OS=Homo sapiens GN=ADAMTSL3 PE=2 SV=4 - [ATL3_HUMAN] Q9Y6K8 Adenylate kinase isoenzyme 5 OS=Homo sapiens GN=AK5 PE=1 SV=2 - [KAD5_HUMAN] P02763 Alpha-1-acid glycoprotein 1 OS=Homo sapiens GN=ORM1 PE=1 SV=1 - [A1AG1_HUMAN] P19652 Alpha-1-acid glycoprotein 2 OS=Homo sapiens GN=ORM2 PE=1 SV=2 - [A1AG2_HUMAN] P01011 Alpha-1-antichymotrypsin OS=Homo sapiens GN=SERPINA3 PE=1 SV=2 - [AACT_HUMAN] P01009 Alpha-1-antitrypsin OS=Homo sapiens GN=SERPINA1 PE=1 SV=3 - [A1AT_HUMAN] P04217 Alpha-1B-glycoprotein OS=Homo sapiens GN=A1BG PE=1 SV=4 - [A1BG_HUMAN] P08697 Alpha-2-antiplasmin OS=Homo sapiens GN=SERPINF2 PE=1 SV=3 - [A2AP_HUMAN] P02765 Alpha-2-HS-glycoprotein OS=Homo sapiens GN=AHSG PE=1 SV=1 - [FETUA_HUMAN] P01023 Alpha-2-macroglobulin OS=Homo sapiens GN=A2M PE=1 SV=3 - [A2MG_HUMAN] P01019 Angiotensinogen OS=Homo sapiens GN=AGT PE=1 SV=1 - [ANGT_HUMAN] Q9NQ90 Anoctamin-2 OS=Homo sapiens GN=ANO2 PE=1 SV=2 - [ANO2_HUMAN] P01008 Antithrombin-III
    [Show full text]
  • Ovarian Gene Expression in the Absence of FIGLA, an Oocyte
    BMC Developmental Biology BioMed Central Research article Open Access Ovarian gene expression in the absence of FIGLA, an oocyte-specific transcription factor Saurabh Joshi*1, Holly Davies1, Lauren Porter Sims2, Shawn E Levy2 and Jurrien Dean1 Address: 1Laboratory of Cellular and Developmental Biology, NIDDK, National Institutes of Health, Bethesda, MD 20892, USA and 2Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, TN 37232, USA Email: Saurabh Joshi* - [email protected]; Holly Davies - [email protected]; Lauren Porter Sims - [email protected]; Shawn E Levy - [email protected]; Jurrien Dean - [email protected] * Corresponding author Published: 13 June 2007 Received: 11 December 2006 Accepted: 13 June 2007 BMC Developmental Biology 2007, 7:67 doi:10.1186/1471-213X-7-67 This article is available from: http://www.biomedcentral.com/1471-213X/7/67 © 2007 Joshi et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Abstract Background: Ovarian folliculogenesis in mammals is a complex process involving interactions between germ and somatic cells. Carefully orchestrated expression of transcription factors, cell adhesion molecules and growth factors are required for success. We have identified a germ-cell specific, basic helix-loop-helix transcription factor, FIGLA (Factor In the GermLine, Alpha) and demonstrated its involvement in two independent developmental processes: formation of the primordial follicle and coordinate expression of zona pellucida genes. Results: Taking advantage of Figla null mouse lines, we have used a combined approach of microarray and Serial Analysis of Gene Expression (SAGE) to identify potential downstream target genes.
    [Show full text]
  • Tumor Initiating but Differentiated Luminal-Like Breast Cancer Cells Are Highly Invasive in the Absence of Basal-Like Activity
    Tumor initiating but differentiated luminal-like breast cancer cells are highly invasive in the absence of basal-like activity Jiyoung Kima, René Villadsena, Therese Sørlieb,c, Louise Fogha, Signe Z. Grønlunda,d, Agla J. Fridriksdottira, Irene Kuhne, Fritz Rankf,1, Vera Timmermans Wielengaf, Hiroko Solvangb,g, Paul A. W. Edwardsh, Anne-Lise Børresen-Daleb,i, Lone Rønnov-Jessend, Mina J. Bisselle,2, and Ole William Petersena,2 aDepartment of Cellular and Molecular Medicine, Centre for Biological Disease Analysis and Danish Stem Cell Centre, Faculty of Health Sciences, University of Copenhagen, DK-2200 Copenhagen N, Denmark; bDepartment of Genetics, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Montebello 0310, Oslo, Norway; cCancer Stem Cell Innovation Center, Oslo University Hospital, Norwegian Radium Hospital, 0310 Oslo, Norway; dCell and Developmental Biology, Department of Biology, University of Copenhagen, DK-2100 Copenhagen Ø, Denmark; eLife Sciences Division, Berkeley National Laboratory, Berkeley, CA 94720; fDepartment of Pathology, Rigshospitalet, DK-2100 Copenhagen Ø, Denmark; gDepartment of Biostatistics, Institute of Basic Medical Science, University of Oslo, 0317 Oslo, Norway; hDepartment of Pathology and Hutchison/MRC Research Centre, University of Cambridge, Cambridge CB2 0X2, United Kingdom; and iK. G. Jebsen Center for Breast Cancer Research, Institute for Clinical Medicine, Faculty of Clinical Medicine, University of Oslo, 0318 Oslo, Norway Contributed by Mina J. Bissell, February 28, 2012 (sent for review January 10, 2012) The majority of human breast cancers exhibit luminal epithelial these contradictions is the concept of tumor cell plasticity, i.e., the differentiation. However, most aggressive behavior, including possibility that differentiated luminal cells must acquire basal-like invasion and purported cancer stem cell activity, are considered traits to become malignant (10–14).
    [Show full text]
  • The Mineralocorticoid Receptor Leads to Increased Expression of EGFR
    www.nature.com/scientificreports OPEN The mineralocorticoid receptor leads to increased expression of EGFR and T‑type calcium channels that support HL‑1 cell hypertrophy Katharina Stroedecke1,2, Sandra Meinel1,2, Fritz Markwardt1, Udo Kloeckner1, Nicole Straetz1, Katja Quarch1, Barbara Schreier1, Michael Kopf1, Michael Gekle1 & Claudia Grossmann1* The EGF receptor (EGFR) has been extensively studied in tumor biology and recently a role in cardiovascular pathophysiology was suggested. The mineralocorticoid receptor (MR) is an important efector of the renin–angiotensin–aldosterone‑system and elicits pathophysiological efects in the cardiovascular system; however, the underlying molecular mechanisms are unclear. Our aim was to investigate the importance of EGFR for MR‑mediated cardiovascular pathophysiology because MR is known to induce EGFR expression. We identifed a SNP within the EGFR promoter that modulates MR‑induced EGFR expression. In RNA‑sequencing and qPCR experiments in heart tissue of EGFR KO and WT mice, changes in EGFR abundance led to diferential expression of cardiac ion channels, especially of the T‑type calcium channel CACNA1H. Accordingly, CACNA1H expression was increased in WT mice after in vivo MR activation by aldosterone but not in respective EGFR KO mice. Aldosterone‑ and EGF‑responsiveness of CACNA1H expression was confrmed in HL‑1 cells by Western blot and by measuring peak current density of T‑type calcium channels. Aldosterone‑induced CACNA1H protein expression could be abrogated by the EGFR inhibitor AG1478. Furthermore, inhibition of T‑type calcium channels with mibefradil or ML218 reduced diameter, volume and BNP levels in HL‑1 cells. In conclusion the MR regulates EGFR and CACNA1H expression, which has an efect on HL‑1 cell diameter, and the extent of this regulation seems to depend on the SNP‑216 (G/T) genotype.
    [Show full text]
  • Pharmacogenomics of Drug-Induced Conditions
    Pharmacogenomics of Drug-Induced Conditions Dan M. Roden, M.D. Professor of Medicine and Pharmacology Director, Oates Institute for Experimental Therapeutics Assistant Vice-Chancellor for Personalized Medicine Vanderbilt University School of Medicine !1 An “idiosyncratic” drug response AR, 78 year old male • Coronary artery disease; 13 years s/p bypass surgery • 2 days after starting dofetilide (potent IKr blocker)… No personal or family history of syncope, sudden death • KCNQ1 variant leading to R583C identified • In vitro: ↓IKs • Not found in >400 ethnically-matched controls • ∴this is likely subclinical congenital Long QT Syndrome !2 Another face of the congenital long QT syndrome !3 Father’s ECG !4 Mother’s ECG !5 9-year-old sister’s ECG !6 Family tree Aunt, cousin, niece with 402 426 syncope 462 405 439 428 (RBBB) 436 428 492 411 419 404 • One episode of syncope, age 20 • Multiple ER visits for acute allergic reactions à epinephrine without incident !7 Mother’s ECG post-exercise !8 Identifying a mutation in KCNQ1 mothersister …YI G FLGLI… …YI D FLGLI… G269D !9 Family tree Aunt, cousin, niece with 402 426 syncope 462 405 439 428 (RBBB) 436 428 492 411 419 404 Incomplete penetrance !10 Grandfather’s ECG !11 Defining the “drug-induced long QT syndrome” • Marked QT prolongation and typical pause-dependent torsades de pointes with drug challenge, both resolving with drug withdrawal • Variants: • Marked QT prolongation (e.g. >520 or 550 or 600 msec), recognized and drug withdrawn (no torsades) • pause-dependent polymorphic VT after administration
    [Show full text]
  • Aquaporin Channels in the Heart—Physiology and Pathophysiology
    International Journal of Molecular Sciences Review Aquaporin Channels in the Heart—Physiology and Pathophysiology Arie O. Verkerk 1,2,* , Elisabeth M. Lodder 2 and Ronald Wilders 1 1 Department of Medical Biology, Amsterdam University Medical Centers, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands; [email protected] 2 Department of Experimental Cardiology, Amsterdam University Medical Centers, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands; [email protected] * Correspondence: [email protected]; Tel.: +31-20-5664670 Received: 29 March 2019; Accepted: 23 April 2019; Published: 25 April 2019 Abstract: Mammalian aquaporins (AQPs) are transmembrane channels expressed in a large variety of cells and tissues throughout the body. They are known as water channels, but they also facilitate the transport of small solutes, gasses, and monovalent cations. To date, 13 different AQPs, encoded by the genes AQP0–AQP12, have been identified in mammals, which regulate various important biological functions in kidney, brain, lung, digestive system, eye, and skin. Consequently, dysfunction of AQPs is involved in a wide variety of disorders. AQPs are also present in the heart, even with a specific distribution pattern in cardiomyocytes, but whether their presence is essential for proper (electro)physiological cardiac function has not intensively been studied. This review summarizes recent findings and highlights the involvement of AQPs in normal and pathological cardiac function. We conclude that AQPs are at least implicated in proper cardiac water homeostasis and energy balance as well as heart failure and arsenic cardiotoxicity. However, this review also demonstrates that many effects of cardiac AQPs, especially on excitation-contraction coupling processes, are virtually unexplored.
    [Show full text]
  • Table S1 the Four Gene Sets Derived from Gene Expression Profiles of Escs and Differentiated Cells
    Table S1 The four gene sets derived from gene expression profiles of ESCs and differentiated cells Uniform High Uniform Low ES Up ES Down EntrezID GeneSymbol EntrezID GeneSymbol EntrezID GeneSymbol EntrezID GeneSymbol 269261 Rpl12 11354 Abpa 68239 Krt42 15132 Hbb-bh1 67891 Rpl4 11537 Cfd 26380 Esrrb 15126 Hba-x 55949 Eef1b2 11698 Ambn 73703 Dppa2 15111 Hand2 18148 Npm1 11730 Ang3 67374 Jam2 65255 Asb4 67427 Rps20 11731 Ang2 22702 Zfp42 17292 Mesp1 15481 Hspa8 11807 Apoa2 58865 Tdh 19737 Rgs5 100041686 LOC100041686 11814 Apoc3 26388 Ifi202b 225518 Prdm6 11983 Atpif1 11945 Atp4b 11614 Nr0b1 20378 Frzb 19241 Tmsb4x 12007 Azgp1 76815 Calcoco2 12767 Cxcr4 20116 Rps8 12044 Bcl2a1a 219132 D14Ertd668e 103889 Hoxb2 20103 Rps5 12047 Bcl2a1d 381411 Gm1967 17701 Msx1 14694 Gnb2l1 12049 Bcl2l10 20899 Stra8 23796 Aplnr 19941 Rpl26 12096 Bglap1 78625 1700061G19Rik 12627 Cfc1 12070 Ngfrap1 12097 Bglap2 21816 Tgm1 12622 Cer1 19989 Rpl7 12267 C3ar1 67405 Nts 21385 Tbx2 19896 Rpl10a 12279 C9 435337 EG435337 56720 Tdo2 20044 Rps14 12391 Cav3 545913 Zscan4d 16869 Lhx1 19175 Psmb6 12409 Cbr2 244448 Triml1 22253 Unc5c 22627 Ywhae 12477 Ctla4 69134 2200001I15Rik 14174 Fgf3 19951 Rpl32 12523 Cd84 66065 Hsd17b14 16542 Kdr 66152 1110020P15Rik 12524 Cd86 81879 Tcfcp2l1 15122 Hba-a1 66489 Rpl35 12640 Cga 17907 Mylpf 15414 Hoxb6 15519 Hsp90aa1 12642 Ch25h 26424 Nr5a2 210530 Leprel1 66483 Rpl36al 12655 Chi3l3 83560 Tex14 12338 Capn6 27370 Rps26 12796 Camp 17450 Morc1 20671 Sox17 66576 Uqcrh 12869 Cox8b 79455 Pdcl2 20613 Snai1 22154 Tubb5 12959 Cryba4 231821 Centa1 17897
    [Show full text]
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • Investigation of Copy Number Variations on Chromosome 21 Detected by Comparative Genomic Hybridization
    Li et al. Molecular Cytogenetics (2018) 11:42 https://doi.org/10.1186/s13039-018-0391-3 RESEARCH Open Access Investigation of copy number variations on chromosome 21 detected by comparative genomic hybridization (CGH) microarray in patients with congenital anomalies Wenfu Li, Xianfu Wang and Shibo Li* Abstract Background: The clinical features of Down syndrome vary among individuals, with those most common being congenital heart disease, intellectual disability, developmental abnormity and dysmorphic features. Complex combination of Down syndrome phenotype could be produced by partially copy number variations (CNVs) on chromosome 21 as well. By comparing individual with partial CNVs of chromosome 21 with other patients of known CNVs and clinical phenotypes, we hope to provide a better understanding of the genotype-phenotype correlation of chromosome 21. Methods: A total of 2768 pediatric patients sample collected at the Genetics Laboratory at Oklahoma University Health Science Center were screened using CGH Microarray for CNVs on chromosome 21. Results: We report comprehensive clinical and molecular descriptions of six patients with microduplication and seven patients with microdeletion on the long arm of chromosome 21. Patients with microduplication have varied clinical features including developmental delay, microcephaly, facial dysmorphic features, pulmonary stenosis, autism, preauricular skin tag, eye pterygium, speech delay and pain insensitivity. We found that patients with microdeletion presented with developmental delay, microcephaly, intrauterine fetal demise, epilepsia partialis continua, congenital coronary anomaly and seizures. Conclusion: Three patients from our study combine with four patients in public database suggests an association between 21q21.1 microduplication of CXADR gene and patients with developmental delay. One patient with 21q22.13 microdeletion of DYRK1A shows association with microcephaly and scoliosis.
    [Show full text]
  • Transcriptomic Analysis of Native Versus Cultured Human and Mouse Dorsal Root Ganglia Focused on Pharmacological Targets Short
    bioRxiv preprint doi: https://doi.org/10.1101/766865; this version posted September 12, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-ND 4.0 International license. Transcriptomic analysis of native versus cultured human and mouse dorsal root ganglia focused on pharmacological targets Short title: Comparative transcriptomics of acutely dissected versus cultured DRGs Andi Wangzhou1, Lisa A. McIlvried2, Candler Paige1, Paulino Barragan-Iglesias1, Carolyn A. Guzman1, Gregory Dussor1, Pradipta R. Ray1,#, Robert W. Gereau IV2, # and Theodore J. Price1, # 1The University of Texas at Dallas, School of Behavioral and Brain Sciences and Center for Advanced Pain Studies, 800 W Campbell Rd. Richardson, TX, 75080, USA 2Washington University Pain Center and Department of Anesthesiology, Washington University School of Medicine # corresponding authors [email protected], [email protected] and [email protected] Funding: NIH grants T32DA007261 (LM); NS065926 and NS102161 (TJP); NS106953 and NS042595 (RWG). The authors declare no conflicts of interest Author Contributions Conceived of the Project: PRR, RWG IV and TJP Performed Experiments: AW, LAM, CP, PB-I Supervised Experiments: GD, RWG IV, TJP Analyzed Data: AW, LAM, CP, CAG, PRR Supervised Bioinformatics Analysis: PRR Drew Figures: AW, PRR Wrote and Edited Manuscript: AW, LAM, CP, GD, PRR, RWG IV, TJP All authors approved the final version of the manuscript. 1 bioRxiv preprint doi: https://doi.org/10.1101/766865; this version posted September 12, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
    [Show full text]
  • Alagille Watson Syndrome (JAG1) Sequencing & Deletion/Duplication
    Lab Dept: Anatomic Pathology Test Name: ALAGILLE WATSON SYNDROME (JAG1) SEQUENCING General Information Lab Order Codes: JAG1 Synonyms: Alagille Watson Syndrome; Cholestasis with Peripheral Pulmonary Stenosis; Arteriohepatic Dysplasia; Syndromatic Hepatic Ductular Hypoplasia; ALGS1 CPT Codes: Sequencing: 81407 – Molecular pathology Level 8 Deletion/Duplication- High Density Targeted Array 81406 – Molecular pathology Level 7 Test Includes: Analysis of bi-directional sequencing. Also includes a targeted array CGH analysis with exon-level resolution to evaluate for a deletion or duplication of one exon of this gene. Logistics Test Indications: Alagille Syndrome is one of the major forms of chronic liver disease in children and is an autosomal dominant disorder with high penetrance but variable expressivity. The main clinical findings include cholestatis due to bile duct paucity, a characteristic facial appearance, and cardiovascular, eye and skeletal abnormalities. Cardiovascular findings include tetralogy of Fallot or singular manifestations thereof, peripheral pulmonary artery stenosis, atrial and/or ventricular septal defects, and coarction of the aorta. Butterfly vertebra is the most common skeletal finding. Other findings include narrowing of interpeduncular spaces in the lumbar spine, spina bifida occulta, and short fingers and ulnae. Facial features consist of broad forehead, triangular face, prominent zygomatic arch and moderate hypertelorism. Posterior embryotoxon and retinal pigmentary changes are common opthalmological findings. ALGS1 is caused by mutations in the JAG1 gene. It encodes jagged-1, a ligand for the Notch receptors. Notch proteins are transmembrane receptors and are components of signaling pathways important for cell fate. JAG1 is expressed in the developing heart and other structures affected in Alagille syndrome. Over 90% of patients with Alagille syndrome have a mutation in the JAG1 gene.
    [Show full text]